CALIBRATE Β· GENOME READEROK
CALIBRATE Β· CLINICAL PLANNEROK
CALIBRATE Β· TRIAL INDEXOK
CALIBRATE Β· SAFETY MONITOROK
CALIBRATE Β· AUDIT LEDGEROK
The reading Method Evidence The panel Request pilot
Multi-agent oncology decision support

A second opinion,
five times over.

OncoAI convenes five specialist agents on a single cancer case. Each reads the evidence on its own, states its confidence, and signs its name β€” so the recommendation you receive is one you can take apart, not just take.

CASE 0071 Β· SPECIMEN INTAKE READING
PatientFemale Β· 38 Β· KPS 80
TumorInvasive ductal carcinoma Β· Stage IV
MolecularHER2 IHC 3+ / FISH 6.2 Β· ER+/PR+ weak Β· gBRCA neg
CNS3 active brain metastases Β· 1.8 cm parietal
History1L T+P+docetaxel Β· 2L T-DM1 β€” progressing
SIGNAL ACQUISITION Β· 5 CHANNELS
AWS Top 300
Harvard HSIL
NeurIPS ML4H
Stanford Medicine AI
Built on AWS Bedrock
01

Five readings, laid side by side.

Every agent reports on the same scale. Where they agree, confidence stacks. Where one holds back, the objection is kept on the record β€” never averaged into silence.

0.00.250.500.751.0
GENOME Β· GN-01
Molecular profile
HER2 amplification confirmed β€” CNS-penetrant HER2 therapy indicated1
0.00
CLINICAL Β· CL-02
Treatment strategy
Tucatinib + trastuzumab + capecitabine β€” Category 1 for active brain mets2
0.00
TRIALS Β· TR-03
Eligibility & referral
Two open trials match HER2+ CNS-active criteria for referral3
0.00
SAFETY Β· SF-04HOLD
Toxicology & interactions
Capecitabine against baseline IBS-D β€” dose-modify, pre-empt diarrhea; review omeprazole interaction4
0.00
AUDIT Β· AU-05
Guideline trace
Every claim resolves to NCCN v1.2025 β€” audit record complete5
0.00
SIGNED
RECOMMENDATION

Proceed with the tucatinib triplet, paired with a proactive GI-mitigation protocol.

Alternate line held in reserve: trastuzumab-deruxtecan, should tolerability dominate. Two trials flagged for referral.

SAFETY HOLD Β· PRESERVED
SF-04 does not block the regimen β€” it conditions it. The objection travels with the recommendation into the record and re-surfaces at every sign-off.

02

Built to be interrogated.

Three commitments separate a reading you can defend from a number you have to trust. Each is a mechanic in the product, not a slogan.

A Β· AUDITABLE

Every claim carries its source.

Superscripts expand to guideline, version, date, page, DOI. Nodes open their reasoning. It is designed to be harder to accept a recommendation blindly than to examine it.

B Β· TIME-BOUND

Confidence has a shelf life.

A recommendation isn't a fact; it's a reading of the evidence as it stood. Confidence decays visibly and re-validates on guideline revision β€” 0.91 today is not 0.91 in ninety days.

C Β· DISSENT KEPT

A held objection stays held.

When one agent dissents, the platform does not smooth it over. The objection is attached to the case and re-surfaces at every point a human signs β€” so nobody inherits a risk they never saw.

03

The record, open to inspection.

Every superscript in the reading resolves here. Open a row to see exactly which line of which guideline the agent stood on.

RefClaimSource
04

The panel.

Five agents, each tuned to one discipline, orchestrated on AWS Bedrock. EMR-first intake, oncology-tuned retrieval over unstructured notes, forward-line planning built in.

GN-01
Genome
Reads the molecular profile and names the driver.
CL-02
Clinical
Plans the regimen and the forward lines.
TR-03
Trials
Matches the case to open, eligible studies.
SF-04
Safety
Screens for toxicity and interactions β€” and holds when needed.
AU-05
Audit
Traces every claim to guideline and keeps the ledger.
ORCHESTRATION Β· AWS BEDROCK EMR-FIRST Β· GENOMICS-OPTIONAL Β· INDIA-FIRST

A lab measures.
An archive remembers.
OncoAI is the account of how the call was made.

FDA CDS non-device posture Β· 21st Century Cures Act Β§3060 Β· a licensed clinician can always independently review the basis for every recommendation.

Bring the case that keeps you up at night.

We're onboarding a small group of design-partner oncology departments. Send a work email and we'll set up a private reading.